Enterome to Present New Clinical Data and Biomarker Findings for EO2463 at the 2024 American Society of Hematology (ASH) Annual Meeting
Paris, France – November 6th, 2024 - Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer based on its unique Mimicry platform, today announced that clinical data from the ongoing Phase 1/2 ‘SIDNEY’ trial of EO2463, an experimental treatment for indolent non-Hodgkin B-cell lymphoma (iNHL), will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Conference, to take place December 7-10, 2024, in San Diego, California, and online.
These presentations will disclose the first data from Phase 2 Cohort 2, evaluating EO2463 as monotherapy for newly diagnosed patients with asymptomatic follicular lymphoma, where EO2463 may offer a safe, proactive immune therapy alternative to the usual “watch-and-wait” observation strategy. The data also report initial findings on a biomarker with potential to predict long-term response to EO2463, both as monotherapy, and in combination with standard treatments, in relapsed/refractory iNHL.
Details of the poster presentations:
- Title: EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab
- Presenting Author: J.C. C. Villasboas Bisneto, M.D., Mayo Clinic
- Session: 622. Lymphomas: Translational – Non-Genetic: Poster I
- Session Date: Saturday, December 7, 2024
- Presentation Time: 5:30 PM – 7:30 PM
- Title: EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/SIDNEY Study
- Presenting Author: Stephen Smith, M.D., Associate Professor, UW Medicine & Fred Hutchinson Cancer Center
- Session: 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III
- Session Date: Monday, December 9, 2024
- Presentation Time: 6:00 PM – 8:00 PM